Alzamend Neuro is trading 7.46% higher at $1.44 in pre-market, with no new company announcement identified to explain the October 9 move.
- The company’s investor-relations page lists September 16 as its latest release.
- Major indices are mixed-to-positive in the supplied market context, but that does not establish a cause for the gain.
- No volume or trading-activity data was provided.